The U.S. Food and Drug Administration approved the sunscreen ingredient bemotrizinol for use in over-the-counter products this week [3].
This approval ends decades of regulatory gridlock in the United States. By allowing a more effective, broad-spectrum UV filter, the agency aims to provide consumers with superior UVA protection to reduce skin damage.
Bemotrizinol, also known as Parsol Shield, was sponsored for approval by DSM Nutritional Products LLC [1]. The ingredient is not new to the global market, having been used for more than 20 years in sunscreens sold across Asia and Europe [2].
Despite its long history of use abroad, the U.S. market had not seen a new sunscreen chemical approval in more than 25 years [1]. This gap left U.S. consumers with fewer options compared to international markets, where more modern filters are standard.
The FDA announced the decision on 10 June 2026 [3]. The agency said that the ingredient is considered safe for consumer use. The move is expected to allow manufacturers to develop formulas that offer more robust protection against the specific wavelengths of ultraviolet radiation that contribute to premature aging and skin cancer.
Industry experts said that the approval addresses a significant void in domestic skincare technology. Because bemotrizinol is highly stable and effective, it allows for better formulation of broad-spectrum products that do not break down as quickly when exposed to the sun.
“The FDA approved the sunscreen ingredient bemotrizinol for use in over-the-counter products this week.”
The approval of bemotrizinol signals a shift in the FDA's approach to sunscreen regulation, moving away from a long period of stagnation. By adopting a filter already vetted by international regulators, the U.S. is aligning its public health standards with those of Europe and Asia, potentially lowering the long-term risk of skin cancer through more effective UVA shielding.
